Aclaris takes a step towards an oral rheumatoid arthritis therapy.
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.